Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:21-27, doi:10.1016/j.jacc.2008.11.008
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horton, E. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Horton, E. S.

STATE-OF-THE-ART PAPER

Defining the Role of Basal and Prandial Insulin for Optimal Glycemic Control

Edward S. Horton, MD*

Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts

Manuscript received April 7, 2008; revised manuscript received November 4, 2008, accepted November 6, 2008.

* Reprint requests and correspondence: Dr. Edward S. Horton, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215 (Email: edward.horton{at}joslin.harvard.edu).

Type 2 diabetes mellitus is a progressive disease characterized by early impairment of beta-cell function and ultimately loss of beta-cell mass. Hence, a single daily injection of a long-acting insulin is commonly initiated after intensification of oral antihyperglycemic therapy. Hemoglobin A1C should be measured every 3 months and therapy adjusted if the target is not met. As beta-cell function continues to decline, it is often necessary to add exogenous bolus insulin therapy, using short-acting insulin analogs or regular insulin. Alternatively, the use of pre-mixed insulin preparations, combining both long-acting and short-acting insulins, may be used.

Key Words: diabetes • hemoglobin A1C • hyperglycemia • insulin

Abbreviations and Acronyms
  A1C = hemoglobin A1C
  CI = confidence interval
  CV = cardiovascular
  HR = hazard ratio
  MI = myocardial infarction
  OAD = oral antihyperglycemic drug
  T2DM = type 2 diabetes mellitus
  TZD = thiazolidinedione




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
C. J. Pepine
Insulin as a cardiovascular therapeutic: improving glycemic control in patients with coronary artery disease.
J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S1 - S2.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement